MAP2K7 and melanoma: MEK2 Q60P mutation was identified as a resistance driver in 3 out of 5 BRAF mutant melanoma patients under dual inhibition of MEK and BRAF, while ERK inhibitors can attenuate the elevated ERK signaling and reverse the refractory phenotype 75.